Literature DB >> 1691431

Neuropeptide content in pancreas and pituitary of obese and diabetes mutant mice: strain and sex differences.

K Timmers1, D L Coleman, N R Voyles, A M Powell, A Rökaeus, L Recant.   

Abstract

The nature of the primary genetic defects in ob/ob and db/db mice are unknown. Both the obese (ob) and diabetes (db) mutations produce similar, multicomponent obese-hyperinsulinemic syndromes when maintained in the same strain of mouse. In an attempt to find differences between these mutations in neuroendocrine function affecting the islets of Langerhans or the pituitary, tissue content of four neuropeptides that are known to be capable of influencing the rate of insulin secretion was examined in obese (ob/ob) and diabetes (db/db) mice. In the first study, C57BL/6Job/ob and control males were studied at 3, 4, and 11 weeks of age. In the second study, db/db mice of both sexes and two inbred strains (C57BL/6J and C57BL/KsJ), which differ markedly in the severity of expression of the diabetes phenotype, were studied at 3 weeks of age, before the development of hyperglycemia and secondary consequences thereof. Immunoreactive peptides were measured in acetic acid extracts of pancreas and pituitary. No differences between male ob/ob and db/db mice of the C57BL/6J strain were found. Marked sex differences in lean control mice were found at 3 weeks of age in pancreatic Met-enkephalin-LI and galanin-LI (with two- to threefold higher content in males). Low pancreatic content (50% to 70% lower than in control mice) of galanin-LI, Met-enkephalin-LI and Leu-enkephalin-LI was associated with hyperinsulinemia in male B6 ob/ob and db/db mice at 3 weeks of age, though not in B6 db/db females and not in BKs db/db mice of either sex.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691431     DOI: 10.1016/0026-0495(90)90252-8

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  4 in total

1.  Possible evidence for endogenous production of a novel galanin-like peptide.

Authors:  Z L Wang; R N Kulkarni; R M Wang; D M Smith; M A Ghatei; P G Byfield; W M Bennet; S R Bloom
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

2.  Dysregulation of the OGF-OGFr pathway and associated diabetic complications.

Authors:  Patricia J McLaughlin; Joseph W Sassani; Ian S Zagon
Journal:  J Diabetes Clin Res       Date:  2021

Review 3.  Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.

Authors:  Patricia J McLaughlin; Joseph W Sassani; Matthew S Klocek; Ian S Zagon
Journal:  Brain Res Bull       Date:  2009-08-14       Impact factor: 4.077

Review 4.  Ocular surface complications in diabetes: The interrelationship between insulin and enkephalin.

Authors:  Indira Purushothaman; Ian S Zagon; Joseph W Sassani; Patricia J McLaughlin
Journal:  Biochem Pharmacol       Date:  2021-07-26       Impact factor: 6.100

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.